Let's not forget their analytics division is doing OK and will continue to grow, irregardless of what happens with their Promarker tech.
$1.129M collected last fy on analytics alone.
Fundamentals are only growing stronger for this Biotech, our cash reserves have increased, commercialization now a reality and new health studies already initiated to further commercialize Promarker platform.
There is also the Therapeutics/Drug Division division that Richard has under his sleeve which is yet to see a strategic commercialization plan.
So far so good in my opinion
Let's not forget their analytics division is doing OK and will...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
39.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $64.65M | |||
| Open | High | Low | Value | Volume |
| 39.0¢ | 40.0¢ | 38.0¢ | $98.01K | 252.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9722 | 38.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.5¢ | 44999 | 1 |
View Market Depth
| Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
| PIQ (ASX) Chart |